Novo Nordisk plans to invest DKK 500m in an expansion of the company’s production facilities in Denmark. They will do this because they wish to generate further capacity for the future production of diabetes tablet Rybelsus.
This article was first published by MedWatch.com
Danish pharmaceutical company Novo Nordisk plans to invest DKK 500m in expanding the company’s production facilities near Copenhagen in Denmark, informs the company in a press release Thursday morning.
According to the company, this is to ensure the company’s production capacity for the diabetes drug Rybelsus. This is a drug based on the molecule semaglutide.
“This investment in our production facilities in Måløv [Danish town, –ed.] is an important step in building and ensuring future capacity for production of Rybelsus (oral semaglutide) in the future,” said Novo Nordisk’s Corporate Vice President for oral semaglutide production Henrik Steen Jensen in the statement.
“Måløv is currently our cornerstone in the production of oral semaglutide. It is critical that we invest timely in capacity expansion to meet the future demands,” he continues.
The production of Rybelsus currently employs around 700 employees in Måløv. Novo Nordisk expects the expansion to be completed in 2022.
Novo Nordisk has continuously made large investments in company facilities. For example, the firm announced in 2020 that it would be investing more than DKK 2bn in one of its Danish factories.
For more news, stay updated at this site.